SuperSaturated Oxygen (SSO2) Therapy is the first and only FDA-approved treatment to significantly reduce myocardial damage in heart attack patients after percutaneous coronary intervention
ZOLL’s TherOx System delivers SSO2 therapy immediately post-PCI to reduce infarct size. (Credit: Business Wire)
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its TherOx® SuperSaturated Oxygen (SSO2) Therapy will be the focus of a panel discussion at the upcoming Society for Cardiovascular Angiography & Interventions (SCAI) Shock virtual conference October 7-8.
The panel discussion, which will be moderated by Babar Basir, D.O., FSCAI (Henry Ford Health System, MI), will take place on Friday, October 8, from 9 to 10 a.m. EDT and will delve into SSO2 Therapy, specifically addressing its FDA-approved indications, clinical data supporting use in STEMI case studies, and an upcoming IDE trial in cardiogenic shock. Presenters include:
Gregg W. Stone, M.D., FACC, MSCAI (Ichan School of Medicine at Mount Sinai, New York)
Steven J. Yakubov, M.D., MSCAI (Ohio Health Heart & Vascular Physicians, OH)
Richard Spears, M.D. FACC (Beaumont Hospital, MI)
“We are thrilled to have these key thought leaders at SCAI Shock examine and discuss SSO2 Therapy and share their real-world experiences,” said Neil Johnston, President of ZOLL Circulation.
SCAI Shock’s goal is to break the 50 percent mortality barrier of cardiogenic shock by bringing together global experts from the fields of interventional cardiology, advanced heart failure, emergency medicine, cardiac critical care, and cardiac surgery to discuss cardiogenic shock, its treatment and new science and technologies.
SuperSaturated Oxygen (SSO2) Therapy is the first and only FDA-approved treatment to significantly reduce myocardial damage in heart attack patients after percutaneous coronary intervention. SSO2 Therapy delivers levels of dissolved oxygen at 7-10 times the normal amount directly to the damaged heart muscle immediately after the coronary artery has been successfully opened via angioplasty and stenting and has been shown in multiple randomized prospective clinical trials to consistently and safely reduce damage and scarring (infarct size) in heart attack patients.1 It is currently indicated for patients who suffer left anterior descending ST-elevation myocardial infarction (LAD STEMI) – also known as widowmaker heart attacks due to the high mortality rate – and are treated within six hours of symptom onset.
SSO2 Therapy was developed by Irvine, California-based TherOx, Inc., now part of ZOLL.
Source: Company Press Release